- Home
- GENK vs PMN Comparison
GENK vs PMN Comparison
Compare GENK & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | PMN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 23.5M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | PMN |
|---|---|---|
| Price | $2.24 | $9.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $72.67 |
| AVG Volume (30 Days) | ★ 52.5K | 43.4K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,449,000.00 | N/A |
| Revenue This Year | $11.49 | N/A |
| Revenue Next Year | $13.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $2.20 | $6.27 |
| 52 Week High | $8.45 | $39.75 |
Technical Indicators
Market Signals| Indicator | GENK | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.17 | 88.77 |
| Support Level | $2.20 | $7.35 |
| Resistance Level | $2.41 | $9.26 |
| Average True Range (ATR) | 0.15 | 0.64 |
| MACD | 0.01 | 0.34 |
| Stochastic Oscillator | 7.69 | 97.33 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.